Novavax

About

Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.

Gaithersburg,Maryland,United States
1001 - 5000
http://www.novavax.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $175.25M
Industries: Biotechnology,Health Care,Pharmaceutical
Founded date: Jan 1, 1987
Number Of Employee: 1001 - 5000
Operating Status: Active
Stock Symbol: nasdaq:NVAX
Legal Name: Novavax AB
Also Known As: Isconova,Molecular Packaging Systems

Novavax is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’s proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.

Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

10

$2.62B

Novavax has raised a total of $2.62B in funding over 2 rounds. Their latest funding was raised on Dec 15, 2022 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 15, 2022	Post-IPO Equity	$74.75M	—	—	—	Detail
Dec 14, 2022	Post-IPO Debt	$175.25M	—	—	—	Detail
Jul 7, 2020	Grant	$1.60B	1	Government of United States of America	—	Detail
Jun 15, 2020	Post-IPO Equity	$200M	1	RA Capital Management	—	Detail
May 11, 2020	Grant	$384M	1	Coalition for Epidemic Preparedness Innovations	—	Detail

Investors

Number of Lead Investors

Number of Investors

4

5

Novavax is funded by 5 investors. Government of United States of America and RA Capital Management are the most recent investors.

Investor Name	Lead Investor	Funding Round
Government of United States of America	Yes	Grant
RA Capital Management	Yes	Post-IPO Equity
Coalition for Epidemic Preparedness Innovations	Yes	Grant
Bill & Melinda Gates Foundation	—	Grant
Innovations Kapital	—	Post-IPO Equity